Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Scope of the Report
Reasons for Doing the Study
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown

Chapter 2 Summary and Highlights
Market Outlook
Market Summary

Chapter 3 Market and Technology Background
Introduction
Risk Factors, Causes and Prevention
Symptoms
Pathophysiology and Clinical Subtypes
Prognosis
Epidemiology
Diagnosis
Biopsy
Laboratory Tests
Blood Tests
Imaging Tests
Treatment
Immunotherapy
PD-1 and PD-L1 Inhibitors
CTLA-4 inhibitors
LAG-3 Inhibitors
Interleukin-2 (IL-2, Proleukin)
Virus Therapy
BRAF inhibitors:
MEK Inhibitors

Chapter 4 Market Dynamics
Market Factors
Market Drivers
Increasing Prevalence of Melanoma
Technological Advancements and Product Launches
Strategic Initiatives
Developments in Early Detection Tools
Patient Advocacy Groups and Awareness
Market Restraints
High Cost of Treatment
Stringent Regulations
Resistance to Therapies
Market Opportunities

Chapter 5 Market Breakdown by Type
Overview
Surgery
Wide Excision
Mohs Surgery
Amputation
Lymph Node Dissection
Therapeutics
Therapeutics by Type
Radiation Therapy

Chapter 6 Market Breakdown by Disease Stage
Overview
Localized Disease
Regional Disease
Distant Disease

Chapter 7 Market Breakdown by Region
Overview
North America
Europe
Asia-Pacific
Rest of the World

Chapter 8 Sustainability: An ESG Perspective
Introduction
ESG Challenges in the Pharmaceutical Industry
ESG Practices in the Market for Melanoma Therapeutics
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study

Chapter 9 Emerging Technologies/ Developments
Introduction
Novel Immune Checkpoint Inhibitors
Adoptive Cell Therapy
Engineered TCR Therapy
Vaccines
Targeted Therapy

Chapter 10 Regulatory Landscape and Pipeline Analysis
Regulatory Landscape
United States
Europe
Japan
Pipeline Analysis

Chapter 11 Patent Analysis
Patent Review by Year
Patent Review by Country
Patent Review

Chapter 12 Competitive Landscape
Mergers and Acquisitions
Strategic Initiatives
Competitive Analysis

Chapter 13 Company Profiles
AMGEN INC.
ASTRAZENECA PLC
BRISTOL-MYERS SQUIBB
ERASCA INC.
F. HOFFMANN-LA ROCHE AG
HUYABIO INTERNATIONAL
IOVANCE BIOTHERAPEUTICS INC.
IO BIOTECH
MERCK & CO. INC.
MODERNA INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.



List of Figures


Summary Figure A : Global Market for Melanoma Therapeutics, 2020-2028
Summary Figure B : Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 1 : Schematic Diagram of Skin Structure
Figure 2 : ABCDE Rule for Melanoma
Figure 3 : Melanoma Staging
Figure 4 : Melanoma by Stages
Figure 5 : Estimated Number of New Skin Melanoma Cases Worldwide for Both Sexes, by Age Group, 2020
Figure 6 : Melanoma Therapeutics Algorithm
Figure 7 : Global Market for Melanoma Therapeutics, by Type, 2020-2028
Figure 8 : Global Market Shares of Melanoma Therapeutics, by Type, 2022
Figure 9 : Global Market for Surgical Treatment of Melanoma, by Region, 2020-2028
Figure 10 : Timeline of FDA Treatment Approvals in Melanoma
Figure 11 : Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 12 : Global Market for Melanoma Therapeutics, by Type, 2020-2028
Figure 13 : Global Market Shares of Melanoma Therapeutics, by Type, 2022
Figure 14 : Global Market for Melanoma Therapeutics for Immunotherapy, by Region, 2020-2028
Figure 15 : Global Market for Melanoma Targeted Therapies, by Region, 2020-2028
Figure 16 : Global Market for Melanoma Chemotherapy, by Region, 2020-2028
Figure 17 : Global Market for Melanoma Radiation Therapy, by Region, 2020-2028
Figure 18 : Global Market for Melanoma Therapeutics, by Disease Stage, 2020-2028
Figure 19 : Global Market Shares of Melanoma Therapeutics, by Disease Stage, 2022
Figure 20 : Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, 2020-2028
Figure 21 : Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, 2020-2028
Figure 22 : Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, 2020-2028
Figure 23 : Global Market for Melanoma Therapeutics, by Region, 2020-2028
Figure 24 : Global Market Shares of Melanoma Therapeutics, by Region, 2022
Figure 25 : North American Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 26 : European Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 27 : Asia-Pacific Market for Melanoma Therapeutics, by Country, 2020-2028
Figure 28 : RoW Market for Melanoma Therapeutics, 2020-2028
Figure 29 : ESG in Market for Melanoma Therapeutics
Figure 30 : Novartis ESG Analysis
Figure 31 : Clinical Trial Analysis
Figure 32 : Shares of Patents Issued on Melanoma Therapeutics, by Year, January 2020 to August 2023
Figure 33 : Global Market Shares of Melanoma Therapeutics, by Company, 2022
Figure 34 : Amgen: Financials, 2021 and 2022
Figure 35 : Amgen: Revenue Share, by Country/Region, 2022
Figure 36 : BMS: Financials, 2021 and 2022
Figure 37 : BMS: Revenue Share, by Business Unit, 2022
Figure 38 : BMS: Revenue Share, by Country/Region, 2022
Figure 39 : Roche: Annual Revenue, 2021 and 2022
Figure 40 : Roche: Revenue Share, by Business Unit, 2022
Figure 41 : Roche: Revenue Share, by Region, 2022
Figure 42 : Merck & Co.: Financials, 2021 and 2022
Figure 43 : Merck & Co.: Revenue Share, by Business Unit, 2022
Figure 44 : Merck & Co.: Revenue Share, by Country/Region, 2022
Figure 45 : Novartis AG: Financials, 2021 and 2022
Figure 46 : Novartis AG: Revenue Share, by Business Unit, 2022
Figure 47 : Novartis AG: Revenue Share, by Region, 2022
Figure 48 : Pfizer Inc.: Financials, 2021 and 2022
Figure 49 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
Figure 50 : Pfizer Inc.: Revenue Share, by Region, 2022

List of Tables


Summary Table A : Global Market for Melanoma Therapeutics, Through 2028
Summary Table B : Global Market for Melanoma Therapeutics, by Region, Through 2028 ($ Millions)
Table 1 : List of Approved Therapies for Melanoma
Table 2 : Global Melanoma Cancer Statistics, by WHO Region, 2020
Table 3 : Global Market for Melanoma Therapeutics, by Type, Through 2028
Table 4 : Recommended Margins for Surgical Excision
Table 5 : Global Market for Surgical Treatment of Melanoma, by Region, Through 2028
Table 6 : Global Market for Melanoma Therapeutics, by Region, Through 2028
Table 7 : Global Market for Melanoma Therapeutics, by Type, Through 2028
Table 8 : Global Market for Melanoma Therapeutics for Immunotherapy, by Region, Through 2028
Table 9 : Global Market for Melanoma Targeted Therapies, by Region, Through 2028
Table 10 : Global Market for Melanoma Chemotherapy, by Region, Through 2028
Table 11 : Global Market for Melanoma Radiation Therapy, by Region, Through 2028
Table 12 : Estimated Costs per Person Diagnosed with Melanoma Over a 5-Year Period, by Disease Stage, 2020
Table 13 : Global Market for Melanoma Therapeutics, by Disease Stage, Through 2028
Table 14 : Global Market for Melanoma Therapeutics for Localized Disease Stage, by Region, Through 2028
Table 15 : Global Market for Melanoma Therapeutics for the Regional Disease Stage, by Region, Through 2028
Table 16 : Global Market for Melanoma Therapeutics for the Distant Metastasis Stage, by Region, Through 2028
Table 17 : Global Market for Melanoma Therapeutics, by Region, Through 2028
Table 18 : North American Market for Melanoma Therapeutics, by Country, Through 2028
Table 19 : European Market for Melanoma Therapeutics, by Country, Through 2028
Table 20 : Estimated Incidence, Mortality and Prevalence of Melanoma in 2020
Table 21 : Asia-Pacific Market for Melanoma Therapeutics, by Country, Through 2028
Table 22 : Key ESG Issues in the Pharmaceutical Industry
Table 23 : Environmental Initiatives by Various Melanoma Therapeutics Companies
Table 24 : ESG Rankings for Companies in the Market for Melanoma Therapeutics for 2023
Table 25 : Industry-Leading Performance Across Priority ESG Ratings
Table 26 : Melanoma Pipeline: Phase II and Phase III Clinical Trials
Table 27 : Patents Issued on Melanoma Therapeutics, by Year, January 2020-August 2023
Table 28 : Patents Issued for Melanoma Therapeutics, by Country, 2020-August 2023
Table 29 : Patents Issued on Melanoma Therapeutics, by Applicant, 2020-August 2023
Table 30 : Mergers and Acquisitions, 2020-2023
Table 31 : Amgen: Financials, 2021 and 2022
Table 32 : Amgen: Marketed Products
Table 33 : BMS: Financials, 2021 and 2022
Table 34 : BMS: Marketed Products
Table 35 : BMS: News, 2019-2023
Table 36 : Roche: Financials, 2021 and 2022
Table 37 : Roche: Marketed Products
Table 38 : Roche: News, 2022
Table 39 : Merck & Co.: Financials, 2021 and 2022
Table 40 : Merck & Co.: Marketed Products
Table 41 : Merck & Co.: News, 2021-2023
Table 42 : Novartis AG: Financials, 2021 and 2022
Table 43 : Novartis AG: Marketed Products
Table 44 : Pfizer Inc.: Financials, 2021 and 2022
Table 45 : Pfizer Inc.: Marketed Products
Table 46 : Pfizer Inc.: News, 2021-2023